{"filing":{"accession_number":"0001104659-26-069810","cik":"0001829635","ticker":"RNAZ","company_name":"Transcode Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"tm2616719d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926069810/tm2616719d1_8k.htm"},"events":[{"id":7080,"run_id":6211,"accession_number":"0001104659-26-069810","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"TransCode disclosed results from its Phase 1a dose escalation clinical trial for TTX-MC138 via press release on June 3, 2026. While this is a clinical trial update rather than a formal earnings release, the disclosure of Phase 1a trial results for a therapeutic candidate is material to investors evaluating the company's pipeline progress and development timeline. The forward-looking statements section explicitly references \"the timing, conduct and results of TransCode's Phase 1a and Phase 2a clinical trials\" and \"the therapeutic potential of TTX-MC138,\" confirming the materiality of these trial results to the company's prospects.","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":3860,"accession_number":"0001104659-26-069810","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"TransCode disclosed results from its Phase 1a dose escalation clinical trial for TTX-MC138 via press release on June 3, 2026. While this is a clinical trial update rather than a formal earnings release, the disclosure of Phase 1a trial results for a therapeutic candidate is material to investors evaluating the company's pipeline progress and development timeline. The forward-looking statements section explicitly references \"the timing, conduct and results of TransCode's Phase 1a and Phase 2a clinical trials\" and \"the therapeutic potential of TTX-MC138,\" confirming the materiality of these trial results to the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:16:55.131657+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3860,"accession_number":"0001104659-26-069810","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"TransCode disclosed results from its Phase 1a dose escalation clinical trial for TTX-MC138 via press release on June 3, 2026. While this is a clinical trial update rather than a formal earnings release, the disclosure of Phase 1a trial results for a therapeutic candidate is material to investors evaluating the company's pipeline progress and development timeline. The forward-looking statements section explicitly references \"the timing, conduct and results of TransCode's Phase 1a and Phase 2a clinical trials\" and \"the therapeutic potential of TTX-MC138,\" confirming the materiality of these trial results to the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:16:55.131657+00:00","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-06-03"}]}